Clinical Trials Logo
  1. Home
  2. Oral Leukoplakia
  3. NCT05727761

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Oral Leukoplakia Clinical Trial

Official title:
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Clinical Trial Summary

This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in > 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In addition, participants who show clinical and histologic improvement should correlate with a significant reduction of Ki-67 proliferative indices in lesions of these participants as compared to baseline.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05727761
Study type Interventional
Source University of Minnesota
Contact Beverly Wuertz
Phone 612-625-3090
Email knier003@umn.edu
Status Not yet recruiting
Phase Phase 2
Start date June 15, 2024
Completion date March 15, 2027
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05505539 - Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia Phase 1
Terminated NCT00176566 - A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting NCT05237960 - Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia Phase 2
Completed NCT04712929 - Candida Associated Cytokines in Oral Leukoplakia
Completed NCT03031899 - Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Terminated NCT00571558 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Phase 1
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting NCT04732741 - Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
Completed NCT00369174 - Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Phase 2
Completed NCT00099021 - Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Phase 2
Active, not recruiting NCT02581137 - Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Phase 2
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Completed NCT00330382 - Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase 2
Not yet recruiting NCT06256809 - Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
Completed NCT00951379 - Pioglitazone for Oral Premalignant Lesions Phase 2
Recruiting NCT04251845 - Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia N/A
Terminated NCT04079491 - Intra and Extra Oral Inspection of Oral Mucosa
Recruiting NCT00767442 - Least Invasive Nonlinear Light Microscopy N/A